These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 17161362

  • 1. CpG oligodeoxynucleotide-induced immunity prevents growth of germinal center-derived B lymphoma cells.
    Ponzio NM, Cutro S, Hu J, Marzouk A, Marshall JD.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):2057-68. PubMed ID: 17161362
    [Abstract] [Full Text] [Related]

  • 2. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent.
    Wild J, Grusby MJ, Schirmbeck R, Reimann J.
    J Immunol; 1999 Aug 15; 163(4):1880-7. PubMed ID: 10438922
    [Abstract] [Full Text] [Related]

  • 3. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
    Wakita D, Chamoto K, Zhang Y, Narita Y, Noguchi D, Ohnishi H, Iguchi T, Sakai T, Ikeda H, Nishimura T.
    Int Immunol; 2006 Mar 15; 18(3):425-34. PubMed ID: 16415100
    [Abstract] [Full Text] [Related]

  • 4. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.
    VanOosten RL, Griffith TS.
    Cancer Res; 2007 Dec 15; 67(24):11980-90. PubMed ID: 18089829
    [Abstract] [Full Text] [Related]

  • 5. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA.
    Ballas ZK, Rasmussen WL, Krieg AM.
    J Immunol; 1996 Sep 01; 157(5):1840-5. PubMed ID: 8757300
    [Abstract] [Full Text] [Related]

  • 6. The augmenting effect of OK432-stimulated B cells on the in vitro generation of anti-tumor cytotoxic T lymphocytes from tumor-draining lymph node cells: the possible role of interleukin-12.
    Shinomiya Y, Harada M, Tamada K, Kurosawa S, Okamoto T, Terao H, Takenoyama M, Ito O, Hirashima C, Li T, Shirakusa T, Nomoto K.
    In Vivo; 1997 Sep 01; 11(1):1-8. PubMed ID: 9067765
    [Abstract] [Full Text] [Related]

  • 7. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
    Chagnon F, Tanguay S, Ozdal OL, Guan M, Ozen ZZ, Ripeau JS, Chevrette M, Elhilali MM, Thompson-Snipes LA.
    Clin Cancer Res; 2005 Feb 01; 11(3):1302-11. PubMed ID: 15709202
    [Abstract] [Full Text] [Related]

  • 8. Germinal center cells are a major IL-5-responsive B cell population in peripheral lymph nodes engaged in the immune response.
    Rabinowitz JL, Tsiagbe VK, Nicknam MH, Thorbecke GJ.
    J Immunol; 1990 Oct 15; 145(8):2440-7. PubMed ID: 2212647
    [Abstract] [Full Text] [Related]

  • 9. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens.
    Jahrsdörfer B, Hartmann G, Racila E, Jackson W, Mühlenhoff L, Meinhardt G, Endres S, Link BK, Krieg AM, Weiner GJ.
    J Leukoc Biol; 2001 Jan 15; 69(1):81-8. PubMed ID: 11200072
    [Abstract] [Full Text] [Related]

  • 10. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A, Oh S, Gharagozlou S, Vedi RN, Ericson K, Low WC, Chen W, Ohlfest JR.
    J Immunother; 2007 Jan 15; 30(8):789-97. PubMed ID: 18049330
    [Abstract] [Full Text] [Related]

  • 11. A novel methionine aminopeptidase-2 inhibitor, PPI-2458, inhibits non-Hodgkin's lymphoma cell proliferation in vitro and in vivo.
    Cooper AC, Karp RM, Clark EJ, Taghizadeh NR, Hoyt JG, Labenski MT, Murray MJ, Hannig G, Westlin WF, Thompson CD.
    Clin Cancer Res; 2006 Apr 15; 12(8):2583-90. PubMed ID: 16638869
    [Abstract] [Full Text] [Related]

  • 12. Capacity of different cell types to stimulate cytotoxic T lymphocyte precursor cells in the presence of interleukin 2.
    Dröge W, Moyers C, Wehrmaker A, Schmidt H, Panknin S, Männel D, Falk W.
    J Immunol; 1984 Jun 15; 132(6):2749-59. PubMed ID: 6233360
    [Abstract] [Full Text] [Related]

  • 13. CpG-C ISS-ODN activation of blood-derived B cells from healthy and chronic immunodeficiency virus-infected macaques.
    Teleshova N, Kenney J, Williams V, Van Nest G, Marshall J, Lifson JD, Sivin I, Dufour J, Bohm R, Gettie A, Pope M.
    J Leukoc Biol; 2006 Feb 15; 79(2):257-67. PubMed ID: 16443827
    [Abstract] [Full Text] [Related]

  • 14. Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells.
    Honeychurch J, Glennie MJ, Illidge TM.
    Cancer Res; 2005 Aug 15; 65(16):7493-501. PubMed ID: 16103104
    [Abstract] [Full Text] [Related]

  • 15. Anti-class II antibodies, but not cytotoxic T-lymphocyte antigen 4-immunoglobulin hybrid molecules, prevent rejection of major histocompatibility complex class II-negative myeloma in T-cell receptor-transgenic mice.
    Dembic Z, Hofgaard PO, Omholt H, Bogen B.
    Scand J Immunol; 2004 Aug 15; 60(1-2):143-52. PubMed ID: 15238083
    [Abstract] [Full Text] [Related]

  • 16. Role of B cells in the stimulation of syngeneic mixed lymphocyte responses.
    Thorbecke GJ, Chapman-Alexander J, Katz IR, Bienenstock A, Asofsky R.
    Behring Inst Mitt; 1983 May 15; (72):107-16. PubMed ID: 6242330
    [Abstract] [Full Text] [Related]

  • 17. In vivo evaluation of the effects of interleukins 2, 4 and 7 on enhancing the immunotherapeutic efficacy of anti-tumor cytotoxic T lymphocytes.
    Lynch DH, Namen AE, Miller RE.
    Eur J Immunol; 1991 Dec 15; 21(12):2977-85. PubMed ID: 1684156
    [Abstract] [Full Text] [Related]

  • 18. Cancer immunotherapeutic effects of novel CpG ODN in murine tumor model.
    Cho HC, Kim BH, Kim K, Park JY, Chang JH, Kim SK.
    Int Immunopharmacol; 2008 Oct 15; 8(10):1401-7. PubMed ID: 18687302
    [Abstract] [Full Text] [Related]

  • 19. [Immunobiological characterization of murine LB leukemia and the LBC cell line].
    Hajos SE, Mongini C, Waldner C, Sánchez Lockhart M, Gravisaco MJ, Roig I, Fernańdez T, Alvarez E.
    Medicina (B Aires); 1996 Oct 15; 56 Suppl 1():45-56. PubMed ID: 9224974
    [Abstract] [Full Text] [Related]

  • 20. PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells.
    Waeckerle-Men Y, Starke A, Wüthrich RP.
    Nephrol Dial Transplant; 2007 Jun 15; 22(6):1527-36. PubMed ID: 17339272
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.